Skip to main content
OpenTrials
Completed

NCT Number: NCT02094417

A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia

The present study will be conducted to evaluate the efficacy and safety of AMG531 and to determine the recommended initial dose of AMG531 on the basis of its efficacy and safety when it is administered subcutaneously (SC) to the Aplastic Anemia (AA) patients with immunosuppressive-therapy refractory thrombocytopenia and also to assess the pharmacokinetics of this product. Its efficacy and safety during the extension period beyond one year will also be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Aplastic Anemia Anemia Anemia, Aplastic Blood Platelet Disorders Bone Marrow Diseases Bone Marrow Failure Disorders Cytopenia Hematologic Diseases Hemic and Lymphatic Diseases Jacobs syndrome Thrombocytopenia

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Korea, Republic of

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who is diagnosed as AA and refractory to immunosuppressive therapy
  • Platelet ≤ 30,000/μL

Exclusion criteria

  • Concurrent active infection not adequately responding to appropriate therapy
  • HIV positivity
  • Bone marrow reticulin grade of > 1
  • Clinically significant cardiac disease
  • Arterial or venous thrombosis within the last 1 year before enrollment
  • Other cause of thrombocytopenia
  • AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)
  • Uncontrolled diabetes
  • Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG + cyclosporine within 6 months before starting study treatment and/or cyclosporine or anabolic hormone within 6 weeks before starting the study treatment
  • History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other thrombopoietin (TPO)-receptor agonist
  • Who plans to conduct hematopoietic stem cell transplantation within 1 year

Treatment and study plan

AMG531

Drug

Subcutaneous, weekly injection

Primary outcomes

  1. Proportion of Subjects Achieving a Platelet Response at Week 9

    Time frame: At week 9

    The proportion of subjects achieving a platelet response at Week 9, and two-sided 95% confidence interval will be calculated. Platelet response is defined as 1) achieving absolute platelet increase of ≥ 20x10^9/L above baseline or 2) increase to ≥ 10x10^9/L and by at least 100% from baseline.

Secondary outcomes

  1. Proportion of Subjects Achieving a Platelet Response

    Time frame: Initial dose evaluation period (Week 9), Week 12, Week 16, Week 24, Week 52, Week 104, and Week 156

    The proportion of subjects with a platelet response in any time during the initial dose evaluation period, Week 1 through Week 12, Week 1 through Week 16, Week 1 through Week 24, Week 1 through Week 52, Week 1 through Week 104 and Week 1 through Week 156.

  2. Proportion of Subjects Achieving Platelet Transfusion Independency

    Time frame: Initial dose evaluation period (Week 9), Week 12, Week 16, Week 24, Week 52, Week 104, and Week 156

    The proportion of subjects achieving platelet transfusion independency in any time during the initial dose evaluation period , Week 1 through Week 12, Week 1 through Week 16, Week 1 through Week 24, Week 1 through Week 52, Week 1 through Week 104, and Week1 through Week 156 will be calculated in the same manner as the primary variables (The number of subjects discontinued or subjects who have missing data will not be calculated). Platelet transfusion independence is defined as achieving transfusion free period of at least 8 consecutive weeks (56 days).

  3. Proportion of Subjects Achieving Erythroid Response and/or Neutrophil Response

    Time frame: Initial dose evaluation period (Week 9), Week 12, Week 16, Week 24, Week 52, Week 104, and Week 156

    The proportion of subjects with erythroid response, neutrophil response and erythroid and/or neutrophil response in any time during the initial dose evaluation period, Week 1 through Week 12, Week 1 through Week 16, Week 1 through Week 24, Week 1 through Week 52, Week 1 through Week 104, and Week1 through Week 156 will be calculated in the same manner as the primary variables (The number of subjects discontinued or subjects who have missing data will not be calculated).

  4. Duration of Platelet Response and Time to Platelet Response

    Time frame: Initial dose evaluation period (Week 9), Week 12, Week 16, Week 24, Week 52, Week 104, and Week 156

    For subjects with a platelet response in any time, time to the initial platelet response and duration of platelet response will be summarized Time to the initial platelet response will be calculated as sampling date (response achieved) minus first dose date of study drug plus 1.

    Duration of platelet response will be calculated as the maximum of the duration of platelet response for each subject, each duration of response calculated as the date when response is disappeared minus the date when response is achieved. The censoring date is defined as the date of the last Platelet examination or EOS whichever archives first.

  5. Proportion of Subjects Achieving Tri-lineage Responses

    Time frame: Initial dose evaluation period (Week 9), Week 12, Week 16, Week 24, Week 52, Week 104, and Week 157

    Tri-lineage response is defined in those achieving platelet response, erythroid response, and neutrophil response all together. The proportion of subjects with tri-lineage response will be calculated in the same manner as the primary variables. Time to tri-lineage response will be summarized in the same manner as time to platelet response. Time to tri-lineage response is defined as duration of the time from Day 1 to the date of platelet response, erythroid response or neutrophil response whichever achieves last in Visit.

  6. Duration of Study Drug Discontinuation While Maintaining Stable Response

    Time frame: Initial dose evaluation period (Week 9), Week 12, Week 16, Week 24, Week 52, Week 104, and Week 156

    The longest duration of study drug discontinuation in subjects while maintaining a stable response is summarized

Sponsors and collaborators

Lead sponsor

Kyowa Kirin Korea Co., Ltd.

Industry

Registry information

Official study title

A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Mar 21, 2014
Registry last updated
Apr 30, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.